Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Levodopa & carbidopa
18 general benefit · 2 Limited Use · 4 not a benefit
AA-Levocarb CR · DIN 02272873 · 100 mg & 25 mg · CR tablet
Limited Use, Reason for Use code 64, 65 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 64, 65 required
Write on scriptone applicable Reason for Use code, 64 or 65 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 64, 65
Reason for Use code 64
For patients with Parkinson's disease who have been treated with conventional therapy (Prolopa or conventional Sinemet), and experienced adverse effects related to drug level fluctuations, such as ON/OFF or wearing off phenomena.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 65
For patients presently requiring anti-parkinsonian drug administration (levodopa/carbidopa) more than three times daily.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
AA-Levocarb CR · DIN 02272873
Manufacturer: A A Pharma Inc.; listing date 2009-08-18
Health Canada: Marketed since 2020-05-26 · brand AA-LEVOCARB CR · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet (extended-release) · route Oral · ingredients CARBIDOPA 25 MG, LEVODOPA 100 MG · company Aa pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAA-Levocarb CR: Formulary list price $0.80 per unit (the source does not state the unit; exact figure $0.7974). What the ministry pays, not the patient.
Ministry pays: $0.7974 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02272873)
Source record
DIN 02272873: AA-Levocarb CR
Raw flags: sec12=Y, sec3=Y
Item: 920000218; group id 931; item number 2219; lccId 00130; manufacturer id AAP
Source form: CR Tab; strength: 100mg & 25mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.7974; ministry $0.7974
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02272873
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75839
Interchangeable products
Sinemet CR · DIN 02028786 · not recorded
Shortage status: resolved shortage (ended March 17, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02272873
Shortage record checked October 6, 2026
Apo-Levocarb · DIN 02195933 · 100 mg & 10 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Levocarb · DIN 02195933
Manufacturer: Apotex Inc.; listing date 1996-12-19
Health Canada: Marketed since 2024-08-27 · brand APO-LEVOCARB · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients LEVODOPA 100 MG, CARBIDOPA 10 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Levocarb: Formulary list price $0.15 per unit (the source does not state the unit; exact figure $0.1479). What the ministry pays, not the patient.
Ministry pays: $0.1479 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02195933)
Source record
DIN 02195933: Apo-Levocarb
Raw flags: sec3=Y
Item: 920000030; group id 932; item number 2221; lccId None; manufacturer id APX
Source form: Tab; strength: 100mg & 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.1479; ministry $0.1479
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02195933
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20189
Interchangeable products
Auro-Levocarb · DIN 02531593 · $0.1479
Jamp Levocarb · DIN 02546396 · $0.1479
Mint-Levocarb · DIN 02457954 · $0.1479
PMS-Levodopa-Carbidopa · DIN 02549719 · $0.1479
Sinemet · DIN 00355658 · not recorded
Teva-Levocarbidopa · DIN 02244494 · $0.1479
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02195933
Shortage record checked October 6, 2026
Apo-Levocarb · DIN 02195941 · 100 mg & 25 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Levocarb · DIN 02195941
Manufacturer: Apotex Inc.; listing date 1996-12-19
Health Canada: Marketed since 2024-08-27 · brand APO-LEVOCARB · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients CARBIDOPA 25 MG, LEVODOPA 100 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Levocarb: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2209). What the ministry pays, not the patient.
Ministry pays: $0.2209 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02195941)
Source record
DIN 02195941: Apo-Levocarb
Raw flags: sec3=Y
Item: 920000036; group id 932; item number 2222; lccId None; manufacturer id APX
Source form: Tab; strength: 100mg & 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.2209; ministry $0.2209
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02195941
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20239
Interchangeable products
Auro-Levocarb · DIN 02531607 · $0.2209
Jamp Levocarb · DIN 02546418 · $0.2209
Mint-Levocarb · DIN 02457962 · $0.2209
PMS-Levodopa-Carbidopa · DIN 02549727 · $0.2209
Sinemet · DIN 00513997 · not recorded
Teva-Levocarbidopa · DIN 02244495 · $0.2209
Shortage status: resolved shortage (ended October 3, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02195941
Shortage record checked October 6, 2026
Auro-Levocarb · DIN 02531593 · 100 mg & 10 mg · tablet
General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Auro-Levocarb · DIN 02531593
Manufacturer: Auro Pharma Inc.; listing date 2023-06-30
Health Canada: Marketed since 2023-04-28 · brand AURO-LEVOCARB · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients LEVODOPA 100 MG, CARBIDOPA 10 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Levocarb: Formulary list price $0.15 per unit (the source does not state the unit; exact figure $0.1479). What the ministry pays, not the patient.
Ministry pays: $0.1479 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02531593)
Source record
DIN 02531593: Auro-Levocarb
Raw flags: sec3=Y
Item: 920000030; group id 932; item number 2221; lccId None; manufacturer id AUR
Source form: Tab; strength: 100mg & 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.1479; ministry $0.1479
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02531593
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102071
Interchangeable products
Apo-Levocarb · DIN 02195933 · $0.1479
Jamp Levocarb · DIN 02546396 · $0.1479
Mint-Levocarb · DIN 02457954 · $0.1479
PMS-Levodopa-Carbidopa · DIN 02549719 · $0.1479
Sinemet · DIN 00355658 · not recorded
Teva-Levocarbidopa · DIN 02244494 · $0.1479
Shortage status: resolved shortage (ended April 7, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02531593
Shortage record checked October 6, 2026
Auro-Levocarb · DIN 02531607 · 100 mg & 25 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Auro-Levocarb · DIN 02531607
Manufacturer: Auro Pharma Inc.; listing date 2023-06-30
Health Canada: Marketed since 2023-04-14 · brand AURO-LEVOCARB · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients LEVODOPA 100 MG, CARBIDOPA 25 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Levocarb: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2209). What the ministry pays, not the patient.
Ministry pays: $0.2209 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02531607)
Source record
DIN 02531607: Auro-Levocarb
Raw flags: sec3=Y
Item: 920000036; group id 932; item number 2222; lccId None; manufacturer id AUR
Source form: Tab; strength: 100mg & 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.2209; ministry $0.2209
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02531607
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102072
Interchangeable products
Apo-Levocarb · DIN 02195941 · $0.2209
Jamp Levocarb · DIN 02546418 · $0.2209
Mint-Levocarb · DIN 02457962 · $0.2209
PMS-Levodopa-Carbidopa · DIN 02549727 · $0.2209
Sinemet · DIN 00513997 · not recorded
Teva-Levocarbidopa · DIN 02244495 · $0.2209
Shortage status: resolved shortage (ended April 15, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02531607
Shortage record checked October 6, 2026
Jamp Levocarb · DIN 02546396 · 100 mg & 10 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Jamp Levocarb · DIN 02546396
Manufacturer: Jamp Pharma Corporation; listing date 2025-01-31
Health Canada: Marketed since 2024-12-13 · brand JAMP LEVOCARB · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients LEVODOPA 100 MG, CARBIDOPA 10 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp Levocarb: Formulary list price $0.15 per unit (the source does not state the unit; exact figure $0.1479). What the ministry pays, not the patient.
Ministry pays: $0.1479 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02546396)
Source record
DIN 02546396: Jamp Levocarb
Raw flags: sec3=Y
Item: 920000030; group id 932; item number 2221; lccId None; manufacturer id JPC
Source form: Tab; strength: 100mg & 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.1479; ministry $0.1479
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02546396
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103509
Interchangeable products
Apo-Levocarb · DIN 02195933 · $0.1479
Auro-Levocarb · DIN 02531593 · $0.1479
Mint-Levocarb · DIN 02457954 · $0.1479
PMS-Levodopa-Carbidopa · DIN 02549719 · $0.1479
Sinemet · DIN 00355658 · not recorded
Teva-Levocarbidopa · DIN 02244494 · $0.1479
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02546396
Shortage record checked October 6, 2026
Jamp Levocarb · DIN 02546418 · 100 mg & 25 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Jamp Levocarb · DIN 02546418
Manufacturer: Jamp Pharma Corporation; listing date 2025-01-31
Health Canada: Marketed since 2024-12-13 · brand JAMP LEVOCARB · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients LEVODOPA 100 MG, CARBIDOPA 25 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp Levocarb: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2209). What the ministry pays, not the patient.
Ministry pays: $0.2209 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02546418)
Source record
DIN 02546418: Jamp Levocarb
Raw flags: sec3=Y
Item: 920000036; group id 932; item number 2222; lccId None; manufacturer id JPC
Source form: Tab; strength: 100mg & 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.2209; ministry $0.2209
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02546418
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103510
Interchangeable products
Apo-Levocarb · DIN 02195941 · $0.2209
Auro-Levocarb · DIN 02531607 · $0.2209
Mint-Levocarb · DIN 02457962 · $0.2209
PMS-Levodopa-Carbidopa · DIN 02549727 · $0.2209
Sinemet · DIN 00513997 · not recorded
Teva-Levocarbidopa · DIN 02244495 · $0.2209
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02546418
Shortage record checked October 6, 2026
Mint-Levocarb · DIN 02457954 · 100 mg & 10 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Mint-Levocarb · DIN 02457954
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2017-02-28
Health Canada: Marketed since 2026-01-12 · brand MINT-LEVOCARB · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients LEVODOPA 100 MG, CARBIDOPA 10 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMint-Levocarb: Formulary list price $0.15 per unit (the source does not state the unit; exact figure $0.1479). What the ministry pays, not the patient.
Ministry pays: $0.1479 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02457954)
Source record
DIN 02457954: Mint-Levocarb
Raw flags: sec3=Y
Item: 920000030; group id 932; item number 2221; lccId None; manufacturer id MIN
Source form: Tab; strength: 100mg & 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.1479; ministry $0.1479
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02457954
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94498
Interchangeable products
Apo-Levocarb · DIN 02195933 · $0.1479
Auro-Levocarb · DIN 02531593 · $0.1479
Jamp Levocarb · DIN 02546396 · $0.1479
PMS-Levodopa-Carbidopa · DIN 02549719 · $0.1479
Sinemet · DIN 00355658 · not recorded
Teva-Levocarbidopa · DIN 02244494 · $0.1479
Shortage status: resolved shortage (ended January 5, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02457954
Shortage record checked October 6, 2026
Mint-Levocarb · DIN 02457962 · 100 mg & 25 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Mint-Levocarb · DIN 02457962
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2017-02-28
Health Canada: Marketed since 2024-09-20 · brand MINT-LEVOCARB · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients CARBIDOPA 25 MG, LEVODOPA 100 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMint-Levocarb: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2209). What the ministry pays, not the patient.
Ministry pays: $0.2209 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02457962)
Source record
DIN 02457962: Mint-Levocarb
Raw flags: sec3=Y
Item: 920000036; group id 932; item number 2222; lccId None; manufacturer id MIN
Source form: Tab; strength: 100mg & 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.2209; ministry $0.2209
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02457962
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94499
Interchangeable products
Apo-Levocarb · DIN 02195941 · $0.2209
Auro-Levocarb · DIN 02531607 · $0.2209
Jamp Levocarb · DIN 02546418 · $0.2209
PMS-Levodopa-Carbidopa · DIN 02549727 · $0.2209
Sinemet · DIN 00513997 · not recorded
Teva-Levocarbidopa · DIN 02244495 · $0.2209
Shortage status: resolved shortage (ended September 20, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02457962
Shortage record checked October 6, 2026
PMS-Levodopa-Carbidopa · DIN 02549719 · 100 mg & 10 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
PMS-Levodopa-Carbidopa · DIN 02549719
Manufacturer: Pharmascience Inc.; listing date 2025-04-30
Health Canada: Marketed since 2025-03-05 · brand PMS-LEVODOPA-CARBIDOPA · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients LEVODOPA 100 MG, CARBIDOPA 10 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPMS-Levodopa-Carbidopa: Formulary list price $0.15 per unit (the source does not state the unit; exact figure $0.1479). What the ministry pays, not the patient.
Ministry pays: $0.1479 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02549719)
Source record
DIN 02549719: PMS-Levodopa-Carbidopa
Raw flags: sec3=Y
Item: 920000030; group id 932; item number 2221; lccId None; manufacturer id PMS
Source form: Tab; strength: 100mg & 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.1479; ministry $0.1479
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02549719
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103853
Interchangeable products
Apo-Levocarb · DIN 02195933 · $0.1479
Auro-Levocarb · DIN 02531593 · $0.1479
Jamp Levocarb · DIN 02546396 · $0.1479
Mint-Levocarb · DIN 02457954 · $0.1479
Sinemet · DIN 00355658 · not recorded
Teva-Levocarbidopa · DIN 02244494 · $0.1479
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02549719
Shortage record checked October 6, 2026
PMS-Levodopa-Carbidopa · DIN 02549727 · 100 mg & 25 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
PMS-Levodopa-Carbidopa · DIN 02549727
Manufacturer: Pharmascience Inc.; listing date 2025-04-30
Health Canada: Marketed since 2025-03-05 · brand PMS-LEVODOPA-CARBIDOPA · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients CARBIDOPA 25 MG, LEVODOPA 100 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPMS-Levodopa-Carbidopa: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2209). What the ministry pays, not the patient.
Ministry pays: $0.2209 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02549727)
Source record
DIN 02549727: PMS-Levodopa-Carbidopa
Raw flags: sec3=Y
Item: 920000036; group id 932; item number 2222; lccId None; manufacturer id PMS
Source form: Tab; strength: 100mg & 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.2209; ministry $0.2209
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02549727
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103854
Interchangeable products
Apo-Levocarb · DIN 02195941 · $0.2209
Auro-Levocarb · DIN 02531607 · $0.2209
Jamp Levocarb · DIN 02546418 · $0.2209
Mint-Levocarb · DIN 02457962 · $0.2209
Sinemet · DIN 00513997 · not recorded
Teva-Levocarbidopa · DIN 02244495 · $0.2209
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02549727
Shortage record checked October 6, 2026
Teva-Levocarbidopa · DIN 02244495 · 100 mg & 25 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Teva-Levocarbidopa · DIN 02244495
Manufacturer: Teva Canada Limited; listing date 2003-01-30
Health Canada: Marketed since 2011-12-13 · brand TEVA-LEVOCARBIDOPA · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients LEVODOPA 100 MG, CARBIDOPA 25 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTeva-Levocarbidopa: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2209). What the ministry pays, not the patient.
Ministry pays: $0.2209 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02244495)
Source record
DIN 02244495: Teva-Levocarbidopa
Raw flags: sec3=Y
Item: 920000036; group id 932; item number 2222; lccId None; manufacturer id TEV
Source form: Tab; strength: 100mg & 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.2209; ministry $0.2209
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02244495
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68471
Interchangeable products
Apo-Levocarb · DIN 02195941 · $0.2209
Auro-Levocarb · DIN 02531607 · $0.2209
Jamp Levocarb · DIN 02546418 · $0.2209
Mint-Levocarb · DIN 02457962 · $0.2209
PMS-Levodopa-Carbidopa · DIN 02549727 · $0.2209
Sinemet · DIN 00513997 · not recorded
Shortage status: active shortage (reported November 28, 2019, last updated August 18, 2022) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02244495
Shortage record checked October 6, 2026
AA-Levocarb CR · DIN 02245211 · 200 mg & 50 mg · CR tablet
Limited Use, Reason for Use code 64, 65 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 64, 65 required
Write on scriptone applicable Reason for Use code, 64 or 65 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 64, 65
Reason for Use code 64
For patients with Parkinson's disease who have been treated with conventional therapy (Prolopa or conventional Sinemet), and experienced adverse effects related to drug level fluctuations, such as ON/OFF or wearing off phenomena.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 65
For patients presently requiring anti-parkinsonian drug administration (levodopa/carbidopa) more than three times daily.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
AA-Levocarb CR · DIN 02245211
Manufacturer: A A Pharma Inc.; listing date 2004-07-20
Health Canada: Marketed since 2020-06-12 · brand AA-LEVOCARB CR · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet (extended-release) · route Oral · ingredients LEVODOPA 200 MG, CARBIDOPA 50 MG · company Aa pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAA-Levocarb CR: Formulary list price $1.43 per unit (the source does not state the unit; exact figure $1.4282). What the ministry pays, not the patient.
Ministry pays: $1.4282 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02245211)
Source record
DIN 02245211: AA-Levocarb CR
Raw flags: sec12=Y, sec3=Y
Item: 920000217; group id 931; item number 2220; lccId 00130; manufacturer id AAP
Source form: CR Tab; strength: 200mg & 50mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.4282; ministry $1.4282
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02245211
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69226
Interchangeable products
Sinemet CR · DIN 00870935 · not recorded
Shortage status: resolved shortage (ended January 2, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02245211
Shortage record checked October 6, 2026
Apo-Levocarb · DIN 02195968 · 250 mg & 25 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Levocarb · DIN 02195968
Manufacturer: Apotex Inc.; listing date 1996-12-19
Health Canada: Marketed since 2024-08-27 · brand APO-LEVOCARB · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients LEVODOPA 250 MG, CARBIDOPA 25 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Levocarb: Formulary list price $0.25 per unit (the source does not state the unit; exact figure $0.2466). What the ministry pays, not the patient.
Ministry pays: $0.2466 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02195968)
Source record
DIN 02195968: Apo-Levocarb
Raw flags: sec3=Y
Item: 920000022; group id 932; item number 2223; lccId None; manufacturer id APX
Source form: Tab; strength: 250mg & 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.2466; ministry $0.2466
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02195968
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20190
Interchangeable products
Auro-Levocarb · DIN 02531615 · $0.2466
Jamp Levocarb · DIN 02546426 · $0.2466
Mint-Levocarb · DIN 02457970 · $0.2466
PMS-Levodopa-Carbidopa · DIN 02549735 · $0.2466
Sinemet · DIN 00328219 · not recorded
Teva-Levocarbidopa · DIN 02244496 · $0.2466
Shortage status: resolved shortage (ended May 7, 2021); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02195968
Shortage record checked October 6, 2026
Auro-Levocarb · DIN 02531615 · 250 mg & 25 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Auro-Levocarb · DIN 02531615
Manufacturer: Auro Pharma Inc.; listing date 2023-06-30
Health Canada: Marketed since 2023-04-14 · brand AURO-LEVOCARB · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients CARBIDOPA 25 MG, LEVODOPA 250 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Levocarb: Formulary list price $0.25 per unit (the source does not state the unit; exact figure $0.2466). What the ministry pays, not the patient.
Ministry pays: $0.2466 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02531615)
Source record
DIN 02531615: Auro-Levocarb
Raw flags: sec3=Y
Item: 920000022; group id 932; item number 2223; lccId None; manufacturer id AUR
Source form: Tab; strength: 250mg & 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.2466; ministry $0.2466
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02531615
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102073
Interchangeable products
Apo-Levocarb · DIN 02195968 · $0.2466
Jamp Levocarb · DIN 02546426 · $0.2466
Mint-Levocarb · DIN 02457970 · $0.2466
PMS-Levodopa-Carbidopa · DIN 02549735 · $0.2466
Sinemet · DIN 00328219 · not recorded
Teva-Levocarbidopa · DIN 02244496 · $0.2466
Shortage status: resolved shortage (ended April 7, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02531615
Shortage record checked October 6, 2026
Jamp Levocarb · DIN 02546426 · 250 mg & 25 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Jamp Levocarb · DIN 02546426
Manufacturer: Jamp Pharma Corporation; listing date 2025-01-31
Health Canada: Marketed since 2024-12-13 · brand JAMP LEVOCARB · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients CARBIDOPA 25 MG, LEVODOPA 250 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp Levocarb: Formulary list price $0.25 per unit (the source does not state the unit; exact figure $0.2466). What the ministry pays, not the patient.
Ministry pays: $0.2466 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02546426)
Source record
DIN 02546426: Jamp Levocarb
Raw flags: sec3=Y
Item: 920000022; group id 932; item number 2223; lccId None; manufacturer id JPC
Source form: Tab; strength: 250mg & 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.2466; ministry $0.2466
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02546426
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103511
Interchangeable products
Apo-Levocarb · DIN 02195968 · $0.2466
Auro-Levocarb · DIN 02531615 · $0.2466
Mint-Levocarb · DIN 02457970 · $0.2466
PMS-Levodopa-Carbidopa · DIN 02549735 · $0.2466
Sinemet · DIN 00328219 · not recorded
Teva-Levocarbidopa · DIN 02244496 · $0.2466
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02546426
Shortage record checked October 6, 2026
PMS-Levodopa-Carbidopa · DIN 02549735 · 250 mg & 25 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
PMS-Levodopa-Carbidopa · DIN 02549735
Manufacturer: Pharmascience Inc.; listing date 2025-04-30
Health Canada: Marketed since 2025-03-05 · brand PMS-LEVODOPA-CARBIDOPA · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients LEVODOPA 250 MG, CARBIDOPA 25 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPMS-Levodopa-Carbidopa: Formulary list price $0.25 per unit (the source does not state the unit; exact figure $0.2466). What the ministry pays, not the patient.
Ministry pays: $0.2466 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02549735)
Source record
DIN 02549735: PMS-Levodopa-Carbidopa
Raw flags: sec3=Y
Item: 920000022; group id 932; item number 2223; lccId None; manufacturer id PMS
Source form: Tab; strength: 250mg & 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.2466; ministry $0.2466
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02549735
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103855
Interchangeable products
Apo-Levocarb · DIN 02195968 · $0.2466
Auro-Levocarb · DIN 02531615 · $0.2466
Jamp Levocarb · DIN 02546426 · $0.2466
Mint-Levocarb · DIN 02457970 · $0.2466
Sinemet · DIN 00328219 · not recorded
Teva-Levocarbidopa · DIN 02244496 · $0.2466
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02549735
Shortage record checked October 6, 2026
Teva-Levocarbidopa · DIN 02244496 · 250 mg & 25 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Teva-Levocarbidopa · DIN 02244496
Manufacturer: Teva Canada Limited; listing date 2002-07-29
Health Canada: Marketed since 2011-12-13 · brand TEVA-LEVOCARBIDOPA · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients LEVODOPA 250 MG, CARBIDOPA 25 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTeva-Levocarbidopa: Formulary list price $0.25 per unit (the source does not state the unit; exact figure $0.2466). What the ministry pays, not the patient.
Ministry pays: $0.2466 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02244496)
Source record
DIN 02244496: Teva-Levocarbidopa
Raw flags: sec3=Y
Item: 920000022; group id 932; item number 2223; lccId None; manufacturer id TEV
Source form: Tab; strength: 250mg & 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.2466; ministry $0.2466
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02244496
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68472
Interchangeable products
Apo-Levocarb · DIN 02195968 · $0.2466
Auro-Levocarb · DIN 02531615 · $0.2466
Jamp Levocarb · DIN 02546426 · $0.2466
Mint-Levocarb · DIN 02457970 · $0.2466
PMS-Levodopa-Carbidopa · DIN 02549735 · $0.2466
Sinemet · DIN 00328219 · not recorded
Shortage status: discontinued (June 12, 2019, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02244496
Shortage record checked October 6, 2026
Teva-Levocarbidopa · DIN 02244494 · 100 mg & 10 mg · tablet
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Teva-Levocarbidopa · DIN 02244494
Manufacturer: Teva Canada Limited; listing date 2003-01-30
Health Canada: Dormant since 2024-02-28 · brand TEVA-LEVOCARBIDOPA · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients LEVODOPA 100 MG, CARBIDOPA 10 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTeva-Levocarbidopa: Formulary list price $0.15 per unit (the source does not state the unit; exact figure $0.1479). What the ministry pays, not the patient.
Ministry pays: $0.1479 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02244494)
Source record
DIN 02244494: Teva-Levocarbidopa
Raw flags: sec3=Y
Item: 920000030; group id 932; item number 2221; lccId None; manufacturer id TEV
Source form: Tab; strength: 100mg & 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.1479; ministry $0.1479
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02244494
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68470
Interchangeable products
Apo-Levocarb · DIN 02195933 · $0.1479
Auro-Levocarb · DIN 02531593 · $0.1479
Jamp Levocarb · DIN 02546396 · $0.1479
Mint-Levocarb · DIN 02457954 · $0.1479
PMS-Levodopa-Carbidopa · DIN 02549719 · $0.1479
Sinemet · DIN 00355658 · not recorded
Shortage status: active shortage (reported March 25, 2020, last updated March 26, 2020) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02244494
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since February 28, 2024 — choose a marketed DIN from the same-category list.
Mint-Levocarb · DIN 02457970 · 250 mg & 25 mg · tablet
General benefitDormant since August 1, 2017 · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Mint-Levocarb · DIN 02457970
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2017-02-28
Health Canada: Dormant since 2017-08-01 · brand MINT-LEVOCARB · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients CARBIDOPA 25 MG, LEVODOPA 250 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMint-Levocarb: Formulary list price $0.25 per unit (the source does not state the unit; exact figure $0.2466). What the ministry pays, not the patient.
Ministry pays: $0.2466 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02457970)
Source record
DIN 02457970: Mint-Levocarb
Raw flags: sec3=Y
Item: 920000022; group id 932; item number 2223; lccId None; manufacturer id MIN
Source form: Tab; strength: 250mg & 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.2466; ministry $0.2466
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02457970
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94500
Interchangeable products
Apo-Levocarb · DIN 02195968 · $0.2466
Auro-Levocarb · DIN 02531615 · $0.2466
Jamp Levocarb · DIN 02546426 · $0.2466
PMS-Levodopa-Carbidopa · DIN 02549735 · $0.2466
Sinemet · DIN 00328219 · not recorded
Teva-Levocarbidopa · DIN 02244496 · $0.2466
Shortage status: active shortage (reported December 8, 2020, estimated to end November 30, 2026, last updated June 17, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02457970
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since August 1, 2017 — choose a marketed DIN from the same-category list.
Sinemet CR · DIN 02028786 · 100 mg & 25 mg · CR tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2019-10-31 — choose a marketed DIN from the same-category list.Discontinued October 31, 2019 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2019-10-31 — choose a marketed DIN from the same-category list.
Write on scriptnot an ODB benefit; the ministry's EAP drug list (August 2026) names this generic but not this DIN: confirm the product with the pharmacy or ministry before an Exceptional Access request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry; Health Canada lists this DIN as Cancelled post market since 2019-10-31 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 64, 65
Reason for Use code 64
For patients with Parkinson's disease who have been treated with conventional therapy (Prolopa or conventional Sinemet), and experienced adverse effects related to drug level fluctuations, such as ON/OFF or wearing off phenomena.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 65
For patients presently requiring anti-parkinsonian drug administration (levodopa/carbidopa) more than three times daily.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Sinemet CR · DIN 02028786
Manufacturer: Merck Frosst Canada Ltd.; listing date 1996-10-01
Health Canada: Cancelled post market since 2019-10-31 · brand SINEMET CR 100/25 · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet (extended-release) · route Oral · ingredients CARBIDOPA 25 MG, LEVODOPA 100 MG · company Merck canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordSinemet CR: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02028786)
Source record
DIN 02028786: Sinemet CR
Raw flags: notABenefit=Y, sec3=Y
Item: 920000218; group id 931; item number 2219; lccId 00130; manufacturer id MFC
Source form: CR Tab; strength: 100mg & 25mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02028786
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14082
Interchangeable products
AA-Levocarb CR · DIN 02272873 · $0.7974
Shortage status: discontinued (October 31, 2019, reported by MERCK CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02028786
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since October 31, 2019 — choose a marketed DIN from the same-category list.
Sinemet · DIN 00355658 · 100 mg & 10 mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-06-16 — choose a marketed DIN from the same-category list.Discontinued June 16, 2017 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-06-16 — choose a marketed DIN from the same-category list.
Write on scriptnot an ODB benefit; the ministry's EAP drug list (August 2026) names this generic but not this DIN: confirm the product with the pharmacy or ministry before an Exceptional Access request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry; Health Canada lists this DIN as Cancelled post market since 2017-06-16 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Sinemet · DIN 00355658
Manufacturer: Merck Frosst Canada Ltd.; listing date 1996-10-01
Health Canada: Cancelled post market since 2017-06-16 · brand SINEMET 100/10 · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients CARBIDOPA 10 MG, LEVODOPA 100 MG · company Merck canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordSinemet: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00355658)
Source record
DIN 00355658: Sinemet
Raw flags: notABenefit=Y, sec3=Y
Item: 920000030; group id 932; item number 2221; lccId None; manufacturer id MFC
Source form: Tab; strength: 100mg & 10mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00355658
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3331
Interchangeable products
Apo-Levocarb · DIN 02195933 · $0.1479
Auro-Levocarb · DIN 02531593 · $0.1479
Jamp Levocarb · DIN 02546396 · $0.1479
Mint-Levocarb · DIN 02457954 · $0.1479
PMS-Levodopa-Carbidopa · DIN 02549719 · $0.1479
Teva-Levocarbidopa · DIN 02244494 · $0.1479
Shortage status: discontinued (June 19, 2017, reported by MERCK CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00355658
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since June 16, 2017 — choose a marketed DIN from the same-category list.
Sinemet · DIN 00513997 · 100 mg & 25 mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2022-07-27 — choose a marketed DIN from the same-category list.Discontinued July 27, 2022 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2022-07-27 — choose a marketed DIN from the same-category list.
Write on scriptnot an ODB benefit; the ministry's EAP drug list (August 2026) names this generic but not this DIN: confirm the product with the pharmacy or ministry before an Exceptional Access request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry; Health Canada lists this DIN as Cancelled post market since 2022-07-27 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Sinemet · DIN 00513997
Manufacturer: Organon Canada Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 2022-07-27 · brand SINEMET · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients LEVODOPA 100 MG, CARBIDOPA 25 MG · company Organon canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordSinemet: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00513997)
Source record
DIN 00513997: Sinemet
Raw flags: notABenefit=Y, sec3=Y
Item: 920000036; group id 932; item number 2222; lccId None; manufacturer id OCI
Source form: Tab; strength: 100mg & 25mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00513997
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4008
Interchangeable products
Apo-Levocarb · DIN 02195941 · $0.2209
Auro-Levocarb · DIN 02531607 · $0.2209
Jamp Levocarb · DIN 02546418 · $0.2209
Mint-Levocarb · DIN 02457962 · $0.2209
PMS-Levodopa-Carbidopa · DIN 02549727 · $0.2209
Teva-Levocarbidopa · DIN 02244495 · $0.2209
Shortage status: discontinued (July 27, 2022, reported by ORGANON CANADA INC.); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00513997
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 27, 2022 — choose a marketed DIN from the same-category list.
Sinemet CR · DIN 00870935 · 200 mg & 50 mg · CR tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2019-02-22 — choose a marketed DIN from the same-category list.Discontinued February 22, 2019 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2019-02-22 — choose a marketed DIN from the same-category list.
Write on scriptnot an ODB benefit; the ministry's EAP drug list (August 2026) names this generic but not this DIN: confirm the product with the pharmacy or ministry before an Exceptional Access request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry; Health Canada lists this DIN as Cancelled post market since 2019-02-22 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 64, 65
Reason for Use code 64
For patients with Parkinson's disease who have been treated with conventional therapy (Prolopa or conventional Sinemet), and experienced adverse effects related to drug level fluctuations, such as ON/OFF or wearing off phenomena.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 65
For patients presently requiring anti-parkinsonian drug administration (levodopa/carbidopa) more than three times daily.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Sinemet CR · DIN 00870935
Manufacturer: Merck Frosst Canada Ltd.; listing date 1996-10-01
Health Canada: Cancelled post market since 2019-02-22 · brand SINEMET CR 200/50 · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet (extended-release) · route Oral · ingredients LEVODOPA 200 MG, CARBIDOPA 50 MG · company Merck canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordSinemet CR: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00870935)
Source record
DIN 00870935: Sinemet CR
Raw flags: notABenefit=Y, sec3=Y
Item: 920000217; group id 931; item number 2220; lccId 00130; manufacturer id MFC
Source form: CR Tab; strength: 200mg & 50mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00870935
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11481
Interchangeable products
AA-Levocarb CR · DIN 02245211 · $1.4282
Shortage status: resolved shortage (ended April 1, 2019); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00870935
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since February 22, 2019 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (N04B, N04BA): coverage varies; not interchangeable
- Benserazide + levodopa (Prolopa 50-12.5): general benefit
- Amantadine (Symmetrel): general benefit, not a benefit
- Bromocriptine (Parlodel): general benefit, not a benefit
- Ropinirole (ReQuip): general benefit, not a benefit
- Selegiline (Eldepryl): general benefit, not a benefit
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered
Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM, RISPERIDONE
Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL
92:00 UNCLASSIFIED THERAPEUTIC AGENTS
· 3 products · General benefit · strengths: 50mg & 12.5mg, 100mg & 25mg, 200mg & 50mg · Cap
· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L
· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab
· 12 products · Listed, not a benefit (4), General benefit (8) · strengths: 0.25mg, 1mg, 2mg, 5mg · Tab
· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 5mg · Tab
· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab
· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab
· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab
· 3 products · General benefit · strengths: 50mg · Tab
· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab
· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L
· 2 products · General benefit · strengths: 1mg/Vial · Inj Pd-Syr Pk, Inj Pd-Vial Pk
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00
and 77 more
Full class listing
Related classes:
Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Availability
Teva-Levocarbidopa · DIN 02244495
Shortage status: active shortage (reported 2019-11-28, last updated 2022-08-18) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02244495
Check this DIN againTeva-Levocarbidopa · DIN 02244496
Shortage status: discontinued (2019-06-12, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02244496
Check this DIN againTeva-Levocarbidopa · DIN 02244494
Shortage status: active shortage (reported 2020-03-25, last updated 2020-03-26) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02244494
Check this DIN againMint-Levocarb · DIN 02457970
Shortage status: active shortage (reported 2020-12-08, estimated to end 2026-11-30, last updated 2026-06-17); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02457970
Check this DIN againSinemet CR · DIN 02028786
Shortage status: discontinued (2019-10-31, reported by MERCK CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02028786
Check this DIN againSinemet · DIN 00355658
Shortage status: discontinued (2017-06-19, reported by MERCK CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00355658
Check this DIN againSinemet · DIN 00513997
Shortage status: discontinued (2022-07-27, reported by ORGANON CANADA INC.); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00513997
Check this DIN again